Catherine Segbefia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherine Segbefia has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuella Amoako
Department of Pediatrics Cape Coast Cape Coast Teaching Hospital
4 shared publications - Lily Gloria Tagoe
Department of Child Health Korle Bu Teaching Hospital Accra Ghana
4 shared publications - Yvonne Dei-Adomakoh
Department of Hematology, University of Ghana Medical School, Korle-Bu Teaching Hospital, Accra, Ghana
4 shared publications - Nihad Salifu
Korle Bu Teaching Hospital Accra Ghana
3 shared publications - Andrew D. Campbell
Division of Hematology Children's National Hospital Washington District of Columbia USA
2 shared publications - Charles Antwi-Boasiako
Department of Physiology, University of Ghana Medical School, University of Ghana , Accra, Greater Accra Region GP 4236
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
A Situational Assessment of the Diagnostic Landscape and Organizational Readiness to Implement Next‐Generation Sequencing at Two Childhood Cancer Treatment Centers in Ghana
Purpose: Next‐generation sequencing (NGS) has emerged as a promising approach to improve diagnostic accuracy, but its feasibility in low‐ and middle‐income countries remains unknown. This study characterized the diagnostic landscape and assessed organizational readiness for NGS implementation at two childhood cancer treatment centers in Accra, Ghana. Methods: A situational assessment of pediatric cancer diagnostics at Korle Bu Teaching Hospital (KBTH) and the Greater Accra Regional Hospital (GARH) was conducted between October and December 2024. Data were collected through site assessments, interviews, and the Organizational Readiness for Implementing Change (ORIC) scale. Descriptive statistics and the Wilcoxon rank‐sum tests were used for analysis. Results: In 2024, approximately 211 and 41 new pediatric cancer cases were diagnosed at KBTH and GARH, respectively. Morphology remained the primary diagnostic modality, with limited access to immunohistochemistry and outsourcing required for immunophenotyping, cytogenetic analyses, and molecular testing. Both centers reported access to essential laboratory resources for NGS testing through a public–private research partnership providing sequencing equipment and technical expertise. However, notable gaps in research infrastructure were identified. Pediatric oncology providers at KBTH and GARH demonstrated high organizational readiness for NGS implementation (median ORIC score: 50/60). Cited barriers to NGS implementation in Ghana included high equipment costs, limited training opportunities, and insufficient political prioritization. Conclusion: While morphology remains the cornerstone of pediatric cancer diagnosis at KBTH and GARH, both centers demonstrated readiness and emerging capacity to implement NGS. However, addressing financial, infrastructural, and workforce barriers will be critical for its sustainable integration into pediatric oncology care in Ghana.
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
Open AccessA Situational Assessment of the Diagnostic Landscape and Organizational Readiness to Implement Next‐Generation Sequencing at Two Childhood Cancer Treatment Centers in Ghana
Purpose: Next‐generation sequencing (NGS) has emerged as a promising approach to improve diagnostic accuracy, but its feasibility in low‐ and middle‐income countries remains unknown. This study characterized the diagnostic landscape and assessed organizational readiness for NGS implementation at two childhood cancer treatment centers in Accra, Ghana. Methods: A situational assessment of pediatric cancer diagnostics at Korle Bu Teaching Hospital (KBTH) and the Greater Accra Regional Hospital (GARH) was conducted between October and December 2024. Data were collected through site assessments, interviews, and the Organizational Readiness for Implementing Change (ORIC) scale. Descriptive statistics and the Wilcoxon rank‐sum tests were used for analysis. Results: In 2024, approximately 211 and 41 new pediatric cancer cases were diagnosed at KBTH and GARH, respectively. Morphology remained the primary diagnostic modality, with limited access to immunohistochemistry and outsourcing required for immunophenotyping, cytogenetic analyses, and molecular testing. Both centers reported access to essential laboratory resources for NGS testing through a public–private research partnership providing sequencing equipment and technical expertise. However, notable gaps in research infrastructure were identified. Pediatric oncology providers at KBTH and GARH demonstrated high organizational readiness for NGS implementation (median ORIC score: 50/60). Cited barriers to NGS implementation in Ghana included high equipment costs, limited training opportunities, and insufficient political prioritization. Conclusion: While morphology remains the cornerstone of pediatric cancer diagnosis at KBTH and GARH, both centers demonstrated readiness and emerging capacity to implement NGS. However, addressing financial, infrastructural, and workforce barriers will be critical for its sustainable integration into pediatric oncology care in Ghana.
- Open Access
- 28 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2799-2811
HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities
Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ 0 ) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to voxelotor ( N = 120) or placebo ( N = 116) for 96 weeks; 195 (83%) were in sub‐Saharan Africa. The primary endpoint, CBFV change from baseline to Week 24, was significantly greater with voxelotor (least‐squares mean change: voxelotor [ n = 114] −12.06 cm/s, placebo [ n = 108] −4.29 cm/s; difference −7.77 cm/s; 95% CI −13.18 to −2.37; p = 0.0048), with significant difference sustained through Week 48. Hemoglobin levels increased at Weeks 24 and 48 with voxelotor. Drug administration was paused in May 2024 when an imbalance of deaths was observed between treatment groups; subsequently, the trial discontinued when all active voxelotor trials were discontinued in September 2024. At study end, median (range) exposure was 84 (3–104) weeks for voxelotor and 84 (3–106) weeks for placebo. The most common SCD‐related treatment‐emergent adverse event was sickle cell anemia with crisis (voxelotor 59.2%; placebo 37.9%). All deaths (voxelotor n = 8; placebo n = 2) were considered unrelated to study drug by treating investigators. Overall, voxelotor showed CBFV reduction in children with SCD and conditional CBFV, suggesting HbS polymerization inhibition has a potential therapeutic role for this group; nevertheless, additional studies evaluating potential regional risks for sickle cell anemia with crisis or mortality are warranted. Trial Registration: ClinicalTrials.gov identifier: NCT04218084
- 28 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2799-2811
Open AccessHOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities
Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ 0 ) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to voxelotor ( N = 120) or placebo ( N = 116) for 96 weeks; 195 (83%) were in sub‐Saharan Africa. The primary endpoint, CBFV change from baseline to Week 24, was significantly greater with voxelotor (least‐squares mean change: voxelotor [ n = 114] −12.06 cm/s, placebo [ n = 108] −4.29 cm/s; difference −7.77 cm/s; 95% CI −13.18 to −2.37; p = 0.0048), with significant difference sustained through Week 48. Hemoglobin levels increased at Weeks 24 and 48 with voxelotor. Drug administration was paused in May 2024 when an imbalance of deaths was observed between treatment groups; subsequently, the trial discontinued when all active voxelotor trials were discontinued in September 2024. At study end, median (range) exposure was 84 (3–104) weeks for voxelotor and 84 (3–106) weeks for placebo. The most common SCD‐related treatment‐emergent adverse event was sickle cell anemia with crisis (voxelotor 59.2%; placebo 37.9%). All deaths (voxelotor n = 8; placebo n = 2) were considered unrelated to study drug by treating investigators. Overall, voxelotor showed CBFV reduction in children with SCD and conditional CBFV, suggesting HbS polymerization inhibition has a potential therapeutic role for this group; nevertheless, additional studies evaluating potential regional risks for sickle cell anemia with crisis or mortality are warranted. Trial Registration: ClinicalTrials.gov identifier: NCT04218084
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-14
A Multidimensional Digital Approach to Pain Assessment in Sickle Cell Disease: A Feasibility Study in Ghana
Purpose: Pain is the most common symptom in sickle cell disease (SCD). Due to a lack of objective markers, pain assessment relies on patient report, which can be highly subjective and lead to miscommunications regarding care. While digital pain tools show promise for improving pain communication, digital literacy barriers and cultural differences may limit their use, particularly in low-resource settings. There is a lack of data on the effectiveness of digital pain tools in sub-Saharan Africa, the region with the highest burden of SCD. Painimation is a digital application that uses animations and graphical images to assess pain location, quality, and intensity. We evaluated its feasibility, acceptability, and utility in a Ghanaian SCD cohort. Patients and Methods: This cross-sectional study was conducted at Korle-Bu Teaching Hospital in Ghana. Individuals age > 10 years with SCD were recruited from the pediatric and adult SCD clinics. Participants were asked to use Painimation and complete a clinical history and an 11-item questionnaire addressing the feasibility, utility, and acceptability of the app. Results: Of the 38 consented patients (66% female, median age: 16 years), 87% reported being comfortable using the touchscreen, and 74% said the app was easy to use. Most participants (68%) reported the app was not burdensome to complete during a pain episode. Participants reported that the body shading (92%), animation selection (92%), and intensity adjustment (87%) features were useful for communicating pain. The app took 102 seconds to complete on average. The most commonly selected pain animation was throbbing (50%), and the most frequently reported pain locations were the legs (35%), back (42%), arms (35%), and chest (35%). Conclusion: Painimation was feasible, acceptable, and useful for pain reporting in this Ghanaian SCD cohort. Pain reports using Painimation mirrored known SCD pain profiles, with predominant throbbing pain and frequent leg and back involvement. Digital health tools may improve pain assessment and management in low-resource settings in sub-Saharan Africa.
- 1 May 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-14
Open AccessA Multidimensional Digital Approach to Pain Assessment in Sickle Cell Disease: A Feasibility Study in Ghana
Purpose: Pain is the most common symptom in sickle cell disease (SCD). Due to a lack of objective markers, pain assessment relies on patient report, which can be highly subjective and lead to miscommunications regarding care. While digital pain tools show promise for improving pain communication, digital literacy barriers and cultural differences may limit their use, particularly in low-resource settings. There is a lack of data on the effectiveness of digital pain tools in sub-Saharan Africa, the region with the highest burden of SCD. Painimation is a digital application that uses animations and graphical images to assess pain location, quality, and intensity. We evaluated its feasibility, acceptability, and utility in a Ghanaian SCD cohort. Patients and Methods: This cross-sectional study was conducted at Korle-Bu Teaching Hospital in Ghana. Individuals age > 10 years with SCD were recruited from the pediatric and adult SCD clinics. Participants were asked to use Painimation and complete a clinical history and an 11-item questionnaire addressing the feasibility, utility, and acceptability of the app. Results: Of the 38 consented patients (66% female, median age: 16 years), 87% reported being comfortable using the touchscreen, and 74% said the app was easy to use. Most participants (68%) reported the app was not burdensome to complete during a pain episode. Participants reported that the body shading (92%), animation selection (92%), and intensity adjustment (87%) features were useful for communicating pain. The app took 102 seconds to complete on average. The most commonly selected pain animation was throbbing (50%), and the most frequently reported pain locations were the legs (35%), back (42%), arms (35%), and chest (35%). Conclusion: Painimation was feasible, acceptable, and useful for pain reporting in this Ghanaian SCD cohort. Pain reports using Painimation mirrored known SCD pain profiles, with predominant throbbing pain and frequent leg and back involvement. Digital health tools may improve pain assessment and management in low-resource settings in sub-Saharan Africa.
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1) , yoag009
Prevalence of ocular complications of sickle cell disease in children seen at a tertiary health facility in Southern Ghana
Objectives: To determine the spectrum of ocular complications of sickle cell disease (SCD) and age of onset of proliferative sickle cell retinopathy (PSR) in children attending the pediatric clinic at a tertiary hospital in southern Ghana. Methods: A cross-sectional study of all children with SCD in steady state, ages 2 to 16 years. Demographic and clinical data were recorded using predesigned forms. The ocular manifestations of SCD were classified as either proliferative or non-proliferative based on the presence or absence of neovascularization, respectively. Results: Included in this study were 294 children, (53.4% males), mean age 9.2 ± 3.7 years and majority had HbSS-199 (67.9%) and HbSC-74 (25.3%) genotypes. Comma-shaped conjunctiva vessels were the commonest anterior segment manifestation occurring in 85% of children. Non-proliferative posterior segment signs included: venous tortuosity 69 (23.5%), salmon-patch hemorrhages 4 (1.4%), iridescent spots 38 (12.9%), and black sunburst 24 (8.2%). Prevalence of PSR of any stage among children with HbSS was 2.5% (5/199) and 8.1% (6/74) among those with HbSC (P = .0366). The earliest age PSR was detected in this cohort was 8 years and for PSR stage 3, 13 years. No child was blind from eye complications of SCD or any other cause. Conclusion: Comma-shaped conjunctiva vessels were the commonest anterior segment manifestation of SCD, and retinal venous tortuosity was the most common posterior segment manifestation. Proliferative retinopathy was more common in HbSC genotype.
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1) , yoag009
Open AccessPrevalence of ocular complications of sickle cell disease in children seen at a tertiary health facility in Southern Ghana
Objectives: To determine the spectrum of ocular complications of sickle cell disease (SCD) and age of onset of proliferative sickle cell retinopathy (PSR) in children attending the pediatric clinic at a tertiary hospital in southern Ghana. Methods: A cross-sectional study of all children with SCD in steady state, ages 2 to 16 years. Demographic and clinical data were recorded using predesigned forms. The ocular manifestations of SCD were classified as either proliferative or non-proliferative based on the presence or absence of neovascularization, respectively. Results: Included in this study were 294 children, (53.4% males), mean age 9.2 ± 3.7 years and majority had HbSS-199 (67.9%) and HbSC-74 (25.3%) genotypes. Comma-shaped conjunctiva vessels were the commonest anterior segment manifestation occurring in 85% of children. Non-proliferative posterior segment signs included: venous tortuosity 69 (23.5%), salmon-patch hemorrhages 4 (1.4%), iridescent spots 38 (12.9%), and black sunburst 24 (8.2%). Prevalence of PSR of any stage among children with HbSS was 2.5% (5/199) and 8.1% (6/74) among those with HbSC (P = .0366). The earliest age PSR was detected in this cohort was 8 years and for PSR stage 3, 13 years. No child was blind from eye complications of SCD or any other cause. Conclusion: Comma-shaped conjunctiva vessels were the commonest anterior segment manifestation of SCD, and retinal venous tortuosity was the most common posterior segment manifestation. Proliferative retinopathy was more common in HbSC genotype.
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Hematology
- Vol. 2026 (1)
Incidence of Induction Toxicities in Childhood Acute Lymphoblastic Leukaemia in Ghana
Introduction: Due to limited supportive care, low‐ and middle‐income countries balance delivering intensive, curative chemotherapy with the risk of treatment‐related toxicity. Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer, and induction is the highest risk period for morbidity and mortality. The study describes induction toxicities among children with ALL at Korle Bu Teaching Hospital, Ghana. Methods: This hospital‐based cohort study involved children aged 1–17 years newly diagnosed with ALL from August 2021 to January 2023. Demographic, clinical and laboratory data were recorded. Descriptive statistics (median [interquartile range]) were used to summarise continuous variables. Frequency and percentages were used to describe categorical variables. Toxicities were graded using the Common Terminology Criteria for Adverse Events, Version 5.0. Results: Thirty‐one children were included. Median age was 5 years (interquartile range [IQR]: 3–10 years). All 31 had at least one induction toxicity of any grade, and 29 (93.4%) had at least one severe (Grade ≥ 3). The most common toxicities were anaemia, thrombocytopenia, sepsis, febrile neutropenia, mucositis and hypertension; bleeding, acute pancreatitis, seizures and hepatotoxicity were less common. Induction mortality rate was 19.3%. There was no association found between age, sex, initial white cell count, treatment protocol and development of any severe toxicity. Conclusion: Severe induction toxicities were common in our cohort with unacceptably high mortality, underscoring the need to prioritise enhanced bedside clinical monitoring for hypertension, improved access to blood products and optimal infection prevention and control practices. Further research exploring the relationship between induction toxicities and patient outcomes is essential.
- 1 January 2026
- Published by Wiley in Advances in Hematology
- Vol. 2026 (1)
Open AccessIncidence of Induction Toxicities in Childhood Acute Lymphoblastic Leukaemia in Ghana
Introduction: Due to limited supportive care, low‐ and middle‐income countries balance delivering intensive, curative chemotherapy with the risk of treatment‐related toxicity. Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer, and induction is the highest risk period for morbidity and mortality. The study describes induction toxicities among children with ALL at Korle Bu Teaching Hospital, Ghana. Methods: This hospital‐based cohort study involved children aged 1–17 years newly diagnosed with ALL from August 2021 to January 2023. Demographic, clinical and laboratory data were recorded. Descriptive statistics (median [interquartile range]) were used to summarise continuous variables. Frequency and percentages were used to describe categorical variables. Toxicities were graded using the Common Terminology Criteria for Adverse Events, Version 5.0. Results: Thirty‐one children were included. Median age was 5 years (interquartile range [IQR]: 3–10 years). All 31 had at least one induction toxicity of any grade, and 29 (93.4%) had at least one severe (Grade ≥ 3). The most common toxicities were anaemia, thrombocytopenia, sepsis, febrile neutropenia, mucositis and hypertension; bleeding, acute pancreatitis, seizures and hepatotoxicity were less common. Induction mortality rate was 19.3%. There was no association found between age, sex, initial white cell count, treatment protocol and development of any severe toxicity. Conclusion: Severe induction toxicities were common in our cohort with unacceptably high mortality, underscoring the need to prioritise enhanced bedside clinical monitoring for hypertension, improved access to blood products and optimal infection prevention and control practices. Further research exploring the relationship between induction toxicities and patient outcomes is essential.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf040
International variations in body mass index within the CASiRe global cohort of sickle cell disease patients
Objectives: Although SCD has traditionally been associated with underweight status, body mass index (BMI) status is shifting globally. As disease-modifying therapies have become available, BMI status has increased. Our aim was to determine the prevalence and risk factors of underweight, overweight, and obese statuses in SCD patients in low-middle and high-income countries. Methods: The CASiRe research consortium cross-sectionally analyzed the association of BMI status (underweight, normal weight, overweight, and obesity) to age, genotype, treatment status, and associated clinical outcomes of 532 SCD patients from Italy, United States, and Ghana. Results: Overall, BMI status varied significantly between countries (underweight P < .001, obesity P < .001, overweight P = .038). Underweight (9.5%-17.2%) and overweight/obesity (14%-27.8%) statuses increased from pediatrics to adults. Hemoglobin (Hgb) SC represented the highest percentage of overweight/obese patients (Hgb SC 49% vs SS/SB0Thal 16%, P < .001). Hydroxyurea use (HgbSS/SB0Thal [-]Hydroxyurea 11% vs [+]Hydroxyurea 32% overweight/obese, P < .001), higher hemoglobin levels (Adults, R = 0.396 P < .001), and genotype (HgbSS/SB0Thal vs SC, P < .001) correlated with overweight/obesity status. Lower hemoglobin (OR 0.77, P < .001) and male sex (OR 0.41 P < .001) were predictors of underweight status while higher hemoglobin (OR 1.38, P < .001) and older age (OR 1.01, P = .031) were predictors of obesity. Underweight status was associated with Ghanian site, male gender, leg ulcers, and microalbuminuria showing that it remains a significant clinical issue. Conclusions: As access to disease-modifying therapy improves for SCD, monitoring for overweight and obesity and their comorbid conditions may be necessary. Underweight SCD patients should be carefully evaluated for end-organ complications, especially in low-resource settings.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf040
International variations in body mass index within the CASiRe global cohort of sickle cell disease patients
Objectives: Although SCD has traditionally been associated with underweight status, body mass index (BMI) status is shifting globally. As disease-modifying therapies have become available, BMI status has increased. Our aim was to determine the prevalence and risk factors of underweight, overweight, and obese statuses in SCD patients in low-middle and high-income countries. Methods: The CASiRe research consortium cross-sectionally analyzed the association of BMI status (underweight, normal weight, overweight, and obesity) to age, genotype, treatment status, and associated clinical outcomes of 532 SCD patients from Italy, United States, and Ghana. Results: Overall, BMI status varied significantly between countries (underweight P < .001, obesity P < .001, overweight P = .038). Underweight (9.5%-17.2%) and overweight/obesity (14%-27.8%) statuses increased from pediatrics to adults. Hemoglobin (Hgb) SC represented the highest percentage of overweight/obese patients (Hgb SC 49% vs SS/SB0Thal 16%, P < .001). Hydroxyurea use (HgbSS/SB0Thal [-]Hydroxyurea 11% vs [+]Hydroxyurea 32% overweight/obese, P < .001), higher hemoglobin levels (Adults, R = 0.396 P < .001), and genotype (HgbSS/SB0Thal vs SC, P < .001) correlated with overweight/obesity status. Lower hemoglobin (OR 0.77, P < .001) and male sex (OR 0.41 P < .001) were predictors of underweight status while higher hemoglobin (OR 1.38, P < .001) and older age (OR 1.01, P = .031) were predictors of obesity. Underweight status was associated with Ghanian site, male gender, leg ulcers, and microalbuminuria showing that it remains a significant clinical issue. Conclusions: As access to disease-modifying therapy improves for SCD, monitoring for overweight and obesity and their comorbid conditions may be necessary. Underweight SCD patients should be carefully evaluated for end-organ complications, especially in low-resource settings.
- Open Access
- 15 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2470-2480
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa
Summary: HbSC disease is a common form of sickle cell disease with significant morbidity and early mortality. Whether hydroxyurea is beneficial for HbSC disease is unknown. Prospective Identification of Variables as Outcomes for Treatment (PIVOT, Trial ID PACTR202108893981080) is a double‐blind, randomised, placebo‐controlled phase II trial of hydroxyurea for people with HbSC, age 5–50 years, in Ghana. After screening, participants were randomised to placebo (standard of care) or hydroxyurea. The primary outcome is the cumulative incidence of haematological toxicities during 12 months of blinded treatment; secondary outcomes include multiple laboratory and clinical assessments. Between April 2022 and June 2023, 112 children and 102 adults were randomised, including 44% females and average age 21.6 ± 14.5 years. Participants had substantial morbidity including previous hospitalisations (93%), vaso‐occlusive events (86%), malaria (79%), often received transfusions (20%), with baseline haemoglobin 11.0 ± 1.2 g/dL and foetal haemoglobin 1.8% ± 1.5%. The spleen was palpable in six children and one adult, and ultrasonographic volumes were collected. Proliferative sickle retinopathy was common (30% children, 75% adults), but proteinuria was less common (3% children, 8% adults). Whole blood viscosity, ektacytometry, point‐of‐sickling, transcranial Doppler, near‐infrared spectrometry (NIRS), 6‐minute walk, and quality of life were also measured. Now fully enrolled, PIVOT will document the safety and potential benefits of hydroxyurea on clinical and laboratory outcomes in HbSC disease.
- 15 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2470-2480
Open AccessBaseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa
Summary: HbSC disease is a common form of sickle cell disease with significant morbidity and early mortality. Whether hydroxyurea is beneficial for HbSC disease is unknown. Prospective Identification of Variables as Outcomes for Treatment (PIVOT, Trial ID PACTR202108893981080) is a double‐blind, randomised, placebo‐controlled phase II trial of hydroxyurea for people with HbSC, age 5–50 years, in Ghana. After screening, participants were randomised to placebo (standard of care) or hydroxyurea. The primary outcome is the cumulative incidence of haematological toxicities during 12 months of blinded treatment; secondary outcomes include multiple laboratory and clinical assessments. Between April 2022 and June 2023, 112 children and 102 adults were randomised, including 44% females and average age 21.6 ± 14.5 years. Participants had substantial morbidity including previous hospitalisations (93%), vaso‐occlusive events (86%), malaria (79%), often received transfusions (20%), with baseline haemoglobin 11.0 ± 1.2 g/dL and foetal haemoglobin 1.8% ± 1.5%. The spleen was palpable in six children and one adult, and ultrasonographic volumes were collected. Proliferative sickle retinopathy was common (30% children, 75% adults), but proteinuria was less common (3% children, 8% adults). Whole blood viscosity, ektacytometry, point‐of‐sickling, transcranial Doppler, near‐infrared spectrometry (NIRS), 6‐minute walk, and quality of life were also measured. Now fully enrolled, PIVOT will document the safety and potential benefits of hydroxyurea on clinical and laboratory outcomes in HbSC disease.
- 8 August 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (11) , e31265
When you just cannot fit neatly into a box—The quagmire of practicing paediatric oncology in low‐ and middle‐income countries
- 8 August 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (11) , e31265
When you just cannot fit neatly into a box—The quagmire of practicing paediatric oncology in low‐ and middle‐income countries
- 18 July 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 95 (4) , e132-e133
Letter: Inexpensive Innovations can Bridge the Infrastructure Gap in Low-Income and Middle-Income Countries: Utility of Transcranial Doppler Studies
- 18 July 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 95 (4) , e132-e133
Letter: Inexpensive Innovations can Bridge the Infrastructure Gap in Low-Income and Middle-Income Countries: Utility of Transcranial Doppler Studies
- Open Access
- 23 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 404-405
Seeing haemoglobin SC: Challenging the misperceptions
Historically understudied and regarded as a mild type of sickle cell disease, HbSC can be associated with significant, progressive complications. Prospective studies are urgently needed to address treatment gaps for HbSC disease.Commentary on: Nelson et al. The clinical spectrum of HbSC sickle cell disease‐not a benign condition. Br J Haematol 2024;205:653‐663.
- 23 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 404-405
Open AccessSeeing haemoglobin SC: Challenging the misperceptions
Historically understudied and regarded as a mild type of sickle cell disease, HbSC can be associated with significant, progressive complications. Prospective studies are urgently needed to address treatment gaps for HbSC disease.Commentary on: Nelson et al. The clinical spectrum of HbSC sickle cell disease‐not a benign condition. Br J Haematol 2024;205:653‐663.